Hims & Hers Stock Rallies on Favorable FDA Panel Vote for Peptide Compound

Shares of Hims & Hers Health (NYSE: HIMS) rallied sharply on Tuesday, defying a broad market downturn after a U.S. Food and Drug Administration advisory panel delivered a favorable recommendation for a peptide compound central to the company's growth strategy.

FDA Panel's Surprise Recommendation

The FDA’s Pharmacy Compounding Advisory Committee voted 8-6, with one abstention, to recommend adding the peptide BPC-157 to the Section 503A Bulks List. This move, if finalized by the FDA, would create a legal pathway for pharmacies to compound prescriptions containing the ingredient.

The outcome was seen as a significant positive for Hims & Hers, as FDA staff had previously expressed skepticism about the compound's supporting evidence, citing limited human data and unresolved safety questions. While the committee's recommendation is non-binding and the FDA has the final authority, investors interpreted the narrow vote as a crucial step toward legitimizing a product category the company is actively pursuing.

Strategic Importance for Hims & Hers

The regulatory development is particularly meaningful for Hims & Hers, which has made a strategic push into the peptide market. The company signaled its commitment to the space with the acquisition of a California-based peptide manufacturing facility in early 2025. Tuesday's vote is viewed as a potential validation of that investment and a de-risking event for its future product pipeline.

Ad

Further catalysts remain on the horizon, as the committee was also scheduled to vote on other peptides, including KPV, TB-500, and MOTS-c, with additional compounds slated for review later in the week.

Market Reaction and Context

The company-specific news drove HIMS stock up 4.9% in afternoon trading, a stark contrast to the wider market sell-off, which saw the S&P 500 fall 1.4% and the Nasdaq Composite drop 2.3%. The stock experienced significant volatility, swinging from a session low of $30.81 to a high of $35.85.

Sentiment heading into the meeting was cautious, as the stock had fallen for three consecutive sessions. The pre-event weakness was compounded by a disclosure that the company's CFO had sold approximately $229,000 worth of shares just ahead of the advisory committee meeting. This backdrop of low expectations helped fuel the sharp rebound on the better-than-feared regulatory news.